TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31036088

Group type: EXPERIMENTAL
Intervention: SIB radiotherapy (95%PTV/PGTV 50.4Gy/59.92Gy/28f)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SIB radiotherapy concurrent and consolidated with S-1
Number of subjects: 300
Study: 28840525

Group type: EXPERIMENTAL
Intervention: SR-LRYGB
Number of subjects: 114

Group type: COMPARATOR
Intervention: LSG
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study: 27179999

Group type: EXPERIMENTAL
Intervention: Ecopipam (single large dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ecopipam (open-label extension phase)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 25033900

Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 23 G vitrectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diabetic subgroup (20 G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diabetic subgroup (23 G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-diabetic subgroup (20 G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-diabetic subgroup (23 G)
Number of subjects: 40
Study: 22686944

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.5 mg/day
Number of subjects: 1912

Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.0 mg/day
Number of subjects: 1912

Group type: EXPERIMENTAL
Intervention: Rivoglitazone (both doses)
Number of subjects: 1912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1912
Study: 20202097

Group type: EXPERIMENTAL
Intervention: Microhybrid ('Point 4'; Kerr, Orange, CA, USA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Packable ('Packable Premise'; Kerr, Orange, CA, USA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nanofilled ('Nanofilled Premise'; Kerr, Orange, CA, USA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All types of restorations
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Packable ('Packable Premise')
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Microhybrid ('Point 4') and Nanofilled ('Nanofilled Premise')
Number of subjects: 35
Study: 18931238

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg preoperatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (preoperatively)
Number of subjects: 50
Study: 16296434

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement containing 1% metronidazole, 1% ciprofloxacin, and 1% cefaclor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional glass-ionomer cement
Number of subjects: 40
Study: 11956510

Group type: EXPERIMENTAL
Intervention: 250 mg L‐796568
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1000 mg L‐796568
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9477752

Group type: EXPERIMENTAL
Intervention: Regimen I: follow-up every three months for the first two years, every sixth month in the third year and thereafter once a year.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Regimen II: follow-up every sixth month the first year, and once a year thereafter.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both regimens (I and II)
Number of subjects: 97
Study: 7618647

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at a dose of 0.7 pmol/kg/min for 3 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 27
Study: 2245458

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (Healthy Women)
Number of subjects: 62
Study: 385095

Group type: EXPERIMENTAL
Intervention: Topical cephradine (1 g applied to the wound at closure)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Systemic cephradine (1 g intravenously at induction and 500 mg 4 h later)
Number of subjects: 248

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control group)
Number of subjects: 248
Study: 31963708

Group type: EXPERIMENTAL
Intervention: 13C‐AceDoPC®
Number of subjects: 0

Group type: COMPARATOR
Intervention: TAG‐DHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 13C‐AceDoPC® and TAG‐DHA
Number of subjects: 0
Study: 30214066

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Genetic Counselor (GC) only
Number of subjects: 197
Study: 29546579

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: COMPARATOR
Intervention: Insulin or Dapagliflozin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Metformin (in vitro)
Number of subjects: 2
Study: 26817957

Group type: EXPERIMENTAL
Intervention: Age ≥ 60 years
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Previous provoked VTE
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Current smoker status
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Overall cancer detection
Number of subjects: 854
Study: 25349316

Group type: EXPERIMENTAL
Intervention: Detailed feedback sessions (18-item evaluation form)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Simple feedback sessions (single-item evaluation form)
Number of subjects: 476

Group type: COMPARATOR
Intervention: No formal presentation feedback (control)
Number of subjects: 476
Study: 23201768

Group type: EXPERIMENTAL
Intervention: 15.0 g egg white protein; 75 kcal
Number of subjects: 30

Group type: COMPARATOR
Intervention: 17.5 g maltodextrin, 78 kcal
Number of subjects: 30
Study: 19960001

Group type: EXPERIMENTAL
Intervention: Alginate (three capsules per day, ingested 30 min before the main meal)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (matching placebo, three capsules per day, ingested 30 min before the main meal)
Number of subjects: 48
Study: 17408408

Group type: EXPERIMENTAL
Intervention: LY517717 100 mg
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: LY517717 125 mg
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: LY517717 150 mg
Number of subjects: 507

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: LY517717 (all doses)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: LY517717 and Enoxaparin
Number of subjects: 507
Study: 16268983

Group type: EXPERIMENTAL
Intervention: Patients without left ventricular hypertrophy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Patients with left ventricular hypertrophy
Number of subjects: 83
Study: 12223253

Group type: EXPERIMENTAL
Intervention: CX516 (300 mg tid to 900 mg tid over 4 weeks)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 10403587

Group type: EXPERIMENTAL
Intervention: High protein/carbohydrate diet (29% protein, 61% carbohydrate, 10% fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High fat diet (9% protein, 30% carbohydrate, 61% fat)
Number of subjects: 8
Study: 8744964

Group type: EXPERIMENTAL
Intervention: Intact pairs presented simultaneously at study and test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombined pairs presented simultaneously at study and test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential presentation at test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit speeded-recognition task
Number of subjects: 0
Study: 2035279

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine
Number of subjects: 139

Group type: COMPARATOR
Intervention: 50 mg clomipramine
Number of subjects: 139
Study: 7071301

Group type: EXPERIMENTAL
Intervention: Auditory feedback stimulus group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stimulus control group
Number of subjects: 40
Study: 30836995

Group type: EXPERIMENTAL
Intervention: Animal drawn carts as the most common mode of transport to primary health facilities
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Median travel time to health facilities
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Financial resources for transport
Number of subjects: 1479

Group type: EXPERIMENTAL
Intervention: Transportation barriers to healthcare access
Number of subjects: 1479
Study: 28697780

Group type: EXPERIMENTAL
Intervention: Sciatic nerve block (SNB)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Local infiltration of analgesia with steroid (LIA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 78
Study: 26032118

Group type: EXPERIMENTAL
Intervention: TAP block (ropivacaine 0.5%, 20 ml on each side)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham block (isotonic saline 0.9%, 20 ml on each side)
Number of subjects: 70
Study: 23859428

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study: 22381601

Group type: EXPERIMENTAL
Intervention: Betamethasone 12-hour dosing interval
Number of subjects: 228

Group type: COMPARATOR
Intervention: Betamethasone 24-hour dosing interval
Number of subjects: 228
Study: 20026554

Group type: EXPERIMENTAL
Intervention: Nutritional counselling by a dietician (D)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Nutritional plus exercise counselling by a dietician and physiotherapist (D + E)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 134
Study: 16675095

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16222900

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Ramipril 10 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MRI assessment of left ventricular structure and function
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: BNP changes during follow-up
Number of subjects: 300
Study: 12171833

Group type: EXPERIMENTAL
Intervention: Individually adjustable intraoral sleep apnea device (ISAD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 20
Study: 10102306

Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 19
Study: 8565983

Group type: EXPERIMENTAL
Intervention: Azithromycin (once daily for three days)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (thrice daily for ten days)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 484

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 484
Study: 2178656

Group type: EXPERIMENTAL
Intervention: Single heparin bolus of 10,000 units (protocol I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heparin bolus of 10,000 units plus continuous infusion of 2000 units/hour (protocol II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heparin infusion at the rate of 2000 units/hour for 24 hours post-angioplasty
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Activated clotting time of arterial blood
Number of subjects: 40
Study: 7451515

Group type: EXPERIMENTAL
Intervention: Ender's pins
Number of subjects: 100

Group type: COMPARATOR
Intervention: Compression sliding hip screw
Number of subjects: 100
Study: 31751333

Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 81
Study: 27658651

Group type: EXPERIMENTAL
Intervention: Novel dispatch protocol
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard dispatch protocol
Number of subjects: 125
Study: 25942482

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN)
Number of subjects: 4640
Study: 23577619

Group type: EXPERIMENTAL
Intervention: Azithromycin and chloroquine fixed-dose combination (AZCQ)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1000
Study: 21505361

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus strain GG (12 billion CFU/day) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19740297

Group type: EXPERIMENTAL
Intervention: Captopril (0.2 mg/kg/day) for 12 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 76
Study: 17845655

Group type: EXPERIMENTAL
Intervention: Cricothyroidotomy on manikin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cricothyroidotomy on simulator
Number of subjects: 70
Study: 16782975

Group type: EXPERIMENTAL
Intervention: Xenon 50-70%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propofol 3-5 mg kg(‐1) h(‐1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment
Number of subjects: 39
Study: 15387358

Group type: EXPERIMENTAL
Intervention: Budesonide plus metronidazole and ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 0
Study: 10923605

Group type: EXPERIMENTAL
Intervention: Topical nasal azelastine (two sprays BID)
Number of subjects: 24
Study: 8833208

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day for 3 years
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day for 3 years
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Alendronate 20 mg/day for 2 years followed by 5 mg/day for the 3rd year
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study: 1435173

Group type: EXPERIMENTAL
Intervention: Isometric resistance training of the knee extensors (30 MVC.d‐1 x 3 d.wk‐1 x 8 wk)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isometric resistance training of the knee extensors
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untrained legs of experimental subjects and both legs of control subjects
Number of subjects: 15
Study: 3911964

Group type: EXPERIMENTAL
Intervention: Suprofen 300 mg suppositories
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Suprofen
Number of subjects: 61
Study: 31627016

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 800
Study: 28679552

Group type: EXPERIMENTAL
Intervention: High-fiber diet (≥18 g NSP/d)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Habitual-fiber diet (control)
Number of subjects: 166
Study: 26024293

Group type: EXPERIMENTAL
Intervention: Wholemeal bread
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alfacar bread
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ordinary bread
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Precooked-Frozen bread
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Candeal-flour bread
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glucose (reference)
Number of subjects: 22
Study: 21950319

Group type: EXPERIMENTAL
Intervention: High power individuals in low group status condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High power individuals in high group status condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High power individuals made accountable for group goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High power individuals in both experiments
Number of subjects: 0
Study: 22136015

Group type: EXPERIMENTAL
Intervention: Electroacupuncture applied to Shenshu (BL 23), Pishu (BL 20), Zusanli (ST 36), and Sanyinjiao (SP 6) for 6 sessions.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blank control group (no intervention).
Number of subjects: 60
Study: 18510043

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 0
Study: 17668564

Group type: EXPERIMENTAL
Intervention: NNRTI (efavirenz; EFV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: non-boosted PI (nelfinavir; NFV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NNRTI + PI (EFV/NFV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: All arms
Number of subjects: 120
Study: 15189781

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 20
Study: 11349017

Group type: EXPERIMENTAL
Intervention: 2.5 x 10(10) HWC plus 25 microg of LT(R192G)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo-vaccine plus 25 microg of LT(R192G)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo-vaccine plus placebo-adjuvant
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 2.5 x 10(10) HWC plus placebo-adjuvant
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8997460

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (0.75 mg/kg) at gluteal site
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (0.75 mg/kg) at deltoid site
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both injection sites (gluteal and deltoid)
Number of subjects: 14
Study: 7700051

Group type: EXPERIMENTAL
Intervention: Severe subgroup (patients requiring amputation or developed necrosis)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mild subgroup (patients receiving conservative treatment of thrombectomy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diseased group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Severe subgroup
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mild subgroup
Number of subjects: 12
Study: 3499161

Group type: EXPERIMENTAL
Intervention: Incremental propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-anaesthetized control group
Number of subjects: 60
Study: 31873788

Group type: EXPERIMENTAL
Intervention: Single bout of whole-body resistance exercise (seven exercises, three sets, 10-12 repetitions at 80% of one-repetition maximum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single bout of whole-body resistance exercise
Number of subjects: 10
Study: 29664983

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis; Genentech) monotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus peripheral laser (combination therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 27196104

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.42
Number of subjects: 654

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 654
Study: 26386793

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/d (5 mg/d for patients ≥75 years and/or <60 kg)
Number of subjects: 9326

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d
Number of subjects: 9326
Study: 23143846

Group type: EXPERIMENTAL
Intervention: Detailed messages
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Non-detailed messages
Number of subjects: 538
Study: 20818480

Group type: EXPERIMENTAL
Intervention: Bright light (2500 lux) during breaks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Normal light (300 lux) during breaks
Number of subjects: 94
Study: 19082803

Group type: EXPERIMENTAL
Intervention: Tang No.1 granule (T1G) for 6 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (general knowledge about IGT)
Number of subjects: 140
Study: 17159259

Group type: EXPERIMENTAL
Intervention: He-Ne laser therapy (wavelength 632.8 nm, output 10mW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral analgesics, local application of anaesthetics, 0.9% saline, and povidine wash
Number of subjects: 50
Study: 15386794

Group type: EXPERIMENTAL
Intervention: Exercise intervention group (n=69)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (n=33)
Number of subjects: 102
Study: 10862636

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isosorbide 5 mononitrate (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls (Losartan and Enalapril)
Number of subjects: 8
Study: 9043272

Group type: EXPERIMENTAL
Intervention: J-pouch irrigations through the efferent ileostomy stoma, daily for 4 weeks.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Kegel exercises (anal muscle strengthening exercises) taught to both groups.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no J-pouch irrigation).
Number of subjects: 58
Study: 1574953

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (400 micrograms iv)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2862223

Group type: EXPERIMENTAL
Intervention: Adjuvant oophorectomy followed by chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFp)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFp) alone
Number of subjects: 327
Study: 30529886

Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fructose (50 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sucrose (50 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sucralose (0.33 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (300 mL plain tap water)
Number of subjects: 16
Study: 29150384

Group type: EXPERIMENTAL
Intervention: Sensory-motor training (SMT), performed 5 times each week for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sensory-motor training (SMT)
Number of subjects: 40
Study: 27146650

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry (MC) juice (60 mL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24963007

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator therapy (control)
Number of subjects: 537
Study: 22407383

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 132
Study: 20105186

Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.03 mg/kg per day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.06 mg/kg per day
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 133